Search

Displaying results 271 - 280 of 359 in total
  1. Drug

    Nicoboxil

    go.drugbank.com/drugs/DB12911
    ApprovedWithdrawn

    Such combination topical analgesics are only available for purchase and use (for humans) in some parts of Europe and Asia, like Germany and Australia [F11, F16].

  2. Drug

    Inaxaplin

    go.drugbank.com/drugs/DB21521
    Investigational

    Inaxaplin is under investigation in clinical trial NCT06794996 (Phase 2b Open-label Study of Inaxaplin in Participants With Proteinuric APOL1 Mediated Kidney Disease).

  3. Drug

    Flupirtine

    go.drugbank.com/drugs/DB06623
    Investigational

    It was approved for the treatment of pain in 1984 in Europe. It is not approved for use in the U.S. or Canada, but is currently in phase II trials for the treatment of fibromyalgia.

  4. Drug

    Pegsitacianine

    go.drugbank.com/drugs/DB19098
    Investigational

    Pegsitacianine is under investigation in clinical trial NCT05576974 (A Phase 2a, Single-dose, Open-label Study to Evaluate Diagnostic Performance and Safety of Pegsitacianine, an Intraoperative Fluorescence

  5. Drug

    Pocenbrodib

    go.drugbank.com/drugs/DB21616
    Investigational

    Pocenbrodib is under investigation in clinical trial NCT06785636 (Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617).

  6. Drug

    Muplestim

    go.drugbank.com/drugs/DB12431
    Investigational

    Muplestim is under investigation in clinical trial NCT00002258 (A Phase I, Open Label Trial to Evaluate the Safety, Tolerance and Biological Effects of SDZ ILE-964 (Recombinant Human Interleukin-3, RhIL

  7. Drug

    Hexobarbital

    go.drugbank.com/drugs/DB01355
    Experimental

    A barbiturate that is effective as a hypnotic and sedative.

  8. Drug

    Elranatamab

    go.drugbank.com/drugs/DB15395
    ApprovedInvestigational

    [L47820] Elranatamab was also approved by the European Commission on December 8, 2023.[L50437]

  9. Drug

    Nirsevimab

    go.drugbank.com/drugs/DB16258
    ApprovedInvestigational

    Nirsevimab (MEDI8897) is a recombinant human immunoglobulin G1 kappa (IgG1ΔΈ) monoclonal antibody used to prevent respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants. It binds to the prefusion conform...

  10. Drug

    Pracinostat

    go.drugbank.com/drugs/DB05223
    Investigational

    Pracinostat is a novel HDAC inhibitor with improved in vivo properties compared to other HDAC inhibitors currently in clinical trials, allowing oral dosing. Data demonstrate that Pracinostat is a potent and effective anti-tumor drug with...